Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix

Eralp Y., Saip P., Sakar B., Kucucuk S., Aydiner A., Dincer M., ...More

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol.13, no.4, pp.497-504, 2003 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 13 Issue: 4
  • Publication Date: 2003
  • Doi Number: 10.1046/j.1525-1438.2003.13325.x
  • Journal Name: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.497-504
  • Keywords: chemotherapy, prognosis, recurrent cervical carcinoma, survival, GYNECOLOGIC-ONCOLOGY-GROUP, SQUAMOUS-CELL CARCINOMA, CISPLATIN PLUS IFOSFAMIDE, FIRST-LINE CHEMOTHERAPY, PHASE-II TRIAL, RANDOMIZED TRIAL, CANCER, PACLITAXEL, CYCLOPHOSPHAMIDE, BLEOMYCIN
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No

Abstract

The aim of this study is to identify the impact of various prognostic factors on survival in patients with recurrent carcinoma of the uterine cervix. Fifty-two patients who were treated with platinum-based chemotherapy for recurrent or metastatic disease were retrospectively evaluated. Twenty-seven patients (90%) had received pelvic radiation as primary treatment.